David Einhorn is Wrong on ‘iPrefs’: Apple Inc. (AAPL)

Page 1 of 2

GREENLIGHT CAPITALShareholder activist David Einhorn has made headlines in recent weeks arguing that Apple Inc. (NASDAQ:AAPL) can unlock shareholder value by issuing $236 billion in preferred shares. But this financial engineering doesn’t create any new wealth, and actually harms the company in the long-term. Apple shareholders should dismiss Einhorn’s ‘silly slideshow’ and ignore these types of financial shenanigans.

In theory…

Einhorn’s proposal is to create a new class of preferred stock that would be distributed to existing shareholders, paying a 4% dividend indefinitely. Einhorn believes this plan could unlock $150 billion in shareholder value.  But let’s put on our i-Banker suits and see how the proposal would work in theory.

The value of a business is determined by the company’s future cash flows discounted by an appropriate interest rate.

Here’s how Apple is roughly valued today.

The problem with Apple Inc. (NASDAQ:AAPL), in Einhorn’s view, is that the company is sub-optimally financed by expensive equity. Investors discount future cash flows at a high rate, reducing the value of the firm.

Preferreds are advantageous because they’re cheaper to issue than equity. Preferred shareholders will accept a lower return because yields are fixed and they’re first in line to receive any dividends.

By issuing $236 billion in preferreds, Apple Inc. (NASDAQ:AAPL) can reduce its cost of capital, lower the rate cash flows are discounted, and increase the value of the firm.

Amazing! Using the super computing power of a napkin, I’ve created $150 billion. Somebody call Harry Potter, because I just found the Philospher’s stone.

Page 1 of 2

Biotech Insider Alert - $5 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 129% in 2.5 years!! Wondering How?

Download a complete edition of our newsletter for free!